Last reviewed · How we verify
bOPV(Liquid)
bOPV is a live attenuated vaccine.
bOPV is a live attenuated vaccine. Used for Prevention of poliomyelitis.
At a glance
| Generic name | bOPV(Liquid) |
|---|---|
| Sponsor | Chinese Academy of Medical Sciences |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
It works by inducing an immune response against poliovirus, providing immunity against poliomyelitis.
Approved indications
- Prevention of poliomyelitis
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
- Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV (PHASE3)
- Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine (PHASE3)
- Trail To Evaluate the Immune Effects of Primary and Booster Immunizations With Poliovirus Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bOPV(Liquid) CI brief — competitive landscape report
- bOPV(Liquid) updates RSS · CI watch RSS
- Chinese Academy of Medical Sciences portfolio CI